Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | STAT6 | P42226 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13580180 | 0.88 | ARG1 (0.36) | ALDH1A1FFAR3MAPK1NPSR1TP53 | |
| SCHEMBL13580169 | 0.88 | ARG1 (0.36) | ALDH1A1FFAR3MAPK1NPSR1TP53 | |
| SCHEMBL19285732 | 0.83 | FFAR3 (0.37) | ALDH1A1FFAR3MAPK1NPSR1TP53 | |
| SCHEMBL3152751 | 0.77 | — | — | |
| SCHEMBL10098974 | 0.77 | — | — | |
| SCHEMBL12285269 | 0.76 | ARG1 (0.33) | ALDH1A1FFAR3MAPK1NPSR1TP53 | |
| SCHEMBL4406432 | 0.76 | ALDH1A1 (0.37) | ALDH1A1FFAR3MAPK1NPSR1TP53 | |
| SCHEMBL17049004 | 0.74 | MEN1 (0.33) | FFAR3MEN1KMT2A | |
| SCHEMBL12988135 | 0.72 | ALDH1A1 (0.35) | ALDH1A1FFAR3 | |
| SCHEMBL1515659 | 0.72 | GRM8 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3147284-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2017-03-29 | — | — | EP | disclosed |
| US-7423067-B2 | N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse | MERCK & CO., INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080076805-A1 | Acyclic Hydrazides as Cannabinoid Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| CN-101048368-A | Acyclic hydrazides as cannabinoid receptor modulators | MERCK & CO INC (US) | 2007-10-03 | — | — | CN | disclosed |
| EP-1807388-A2 | ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1490043-A4 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006041797-A2 | ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20050239828-A1 | Spirocyclic amides as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1490043-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082190-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| US-4220795-A | MODIFIERS OF SMOOTH MUSCLE ACTIVITY, PLATELET ANTIAGGREGATING AGENTS, GASTRIC ANTISCRETORY AGENTS, BRONCHODILATORS | MILES LABORATORIES, INC. (US) | 1980-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076805-A1 | Acyclic Hydrazides as Cannabinoid Receptor Modulators | CNR1, CNR2, FAAH | ALDH1A1 2539/4885FFAR3 531/4885MAPK1 1651/4885 |
| US-20050239828-A1 | Spirocyclic amides as cannabinoid receptor modulators | CNR1, CNR2, MAG | ALDH1A1 2505/4885FFAR3 519/4885MAPK1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.